Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K
March 31 2023 - 10:06AM
InvestorsHub NewsWire
SAN DIEGO, CA -- March 31, 2023 -- InvestorsHub NewsWire --
Sigyn Therapeutics, Inc. (OTCQB:
SIGY) (“Sigyn Therapeutics” or the “Company”), a
development-stage company that creates blood purification
technologies to address unmet needs in global health, announced
today the filing of its Form 10-K annual report with the United
States Securities and Exchange Commission ("SEC") for the year
ended December 31, 2022.
During the course of 2022, the Company continued its advancement
of Sigyn Therapy™ toward first-in-human studies. Based on a
demonstrated ability to deplete viral pathogens, bacterial toxins
and inflammatory cytokines from human blood plasma, Sigyn Therapy
establishes a strategy to address pathogen-associated inflammatory
disorders that are not treatable with drug
therapies. Candidate treatment indications include endotoxemia
and inflammation in end-stage renal disease patients, sepsis
(leading cause of hospital deaths), community acquired pneumonia (a
leading cause of death among infectious diseases), and emerging
pandemic threats.
During 2022, the Company also designed and initiated the
development of a cancer treatment system to enhance the delivery of
chemotherapy and reduce its toxicity. Additionally, Sigyn
Therapeutics broadened its intellectual property portfolio,
expanded its corporate team, strengthened its Board of Directors,
added respected industry thought leaders to its Science Advisory
Board, and commenced trading of its securities on the
OTCQB® Venture Exchange.
Summary of 2022 Financial Results
For the year ended December 31, 2022, the Company had a loss
from operations of approximately $2.1 million, compared to an
operating loss of approximately $2.0 for the comparable period of
2021. The Company’s net loss for the year ended December 31, 2022,
was approximately $2.9 million, or approximately $0.08 per share,
compared to a net loss of approximately $3.0 million, or
approximately $0.08 per share, for the comparable period in 2021.
In 2022, net cash used in operating activities was approximately
$1.8 million.
A copy of Sigyn Therapeutics’ annual report is available on the
SEC's website at www.sec.gov,
and on the Company's website at www.sigyntherapeutics.com under "Financial Info"
in the Investors section.
About Sigyn Therapeutics™
Sigyn Therapeutics is a development-stage company focused on
creating therapeutic solutions to address unmet needs in global
health. Sigyn Therapy™, the Company’s lead product candidate, is a
broad-spectrum blood purification technology designed to treat
pathogen-associated inflammatory disorders that are not addressed
with approved drug therapies.
Candidate treatment indications for Sigyn Therapy include
endotoxemia and concurrent inflammation in end-stage renal disease
patients, sepsis (leading cause of hospital deaths), community
acquired pneumonia (a leading cause of death among infectious
diseases), and emerging pandemic threats.
The Company’s development pipeline includes a cancer treatment
system comprised of ChemoPrep™ to enhance the delivery of FDA
approved chemotherapeutic agents and ChemoPure™ to reduce
chemotherapy toxicity. To learn more about Sigyn Therapeutics,
visit: www.SigynTherapeutics.com.
Cautionary Note Regarding Forward-Looking
Statements
This information in this press release contains forward-looking
statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve
substantial risks and uncertainties. All statements contained in
this summary are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 that involve risks and
uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect," "intend," "plan," "project,"
"will," "projections," "estimate," "potentially" or similar
expressions constitute forward-looking statements. Such
forward-looking statements are subject to significant risks and
uncertainties and actual results may differ materially from the
results anticipated in the forward-looking statements. These
forward-looking statements are based upon Sigyn's current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Factors that may contribute to such
differences may include, without limitation, the Company's ability
to clinically advance Sigyn Therapy in human studies required for
market clearance, the Company's ability to manufacture Sigyn
Therapy, the Company's ability to raise capital resources, and
other potential risks. The foregoing list of risks and
uncertainties is illustrative but is not exhaustive. Additional
factors that could cause results to differ materially from those
anticipated in forward-looking statements can be found under the
caption "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2021, and in the Company's other
filings with the Securities and Exchange Commission, including its
quarterly Reports on Form 10-Q. All forward-looking statements
contained in this report speak only as of the date on which they
were made. Except as may be required by law, the Company does not
intend, nor does it undertake any duty, to update this information
to reflect future events or circumstances.
Contacts:
Jim Joyce
Chairman, CEO
Phone/Text: 619.368.2000
Email: jj@SigynTherapeutics.com
Sigyn Therapeutics (QB) (USOTC:SIGY)
Historical Stock Chart
From Sep 2023 to Oct 2023
Sigyn Therapeutics (QB) (USOTC:SIGY)
Historical Stock Chart
From Oct 2022 to Oct 2023